Navigation Links
Deep Breeze Ltd. Launches Unique Non-Invasive, Radiation-Free Pulmonary Imaging System in the U.S.
Date:10/22/2007

CHICAGO, Oct. 22 /PRNewswire/ -- Deep Breeze Ltd., the leader in Vibration response imaging (VRI(TM)) technology, today announced that its VRIxp(TM) lung imaging system will now be available in the US. The VRIxp(TM) is a pulmonary imaging system that allows healthcare providers to see and monitor lung sounds without exposing the patient to radiation or an invasive procedure. The Company announced the phased U.S. launch at The American College of Chest Physicians (CHEST 2007) annual meeting taking place from October 20-25. The system is on display at booth #710.

The non-invasive and radiation-free lung imaging system records lung sounds from sensors applied to a patient's back. The system then uses an algorithm to convert these data into images. Changes in tissue composition and airflow affect the vibration of sounds within the lung, which is reflected on the image of the VRIxp(TM) system. This information on the patient's lung condition enables the physician to manage and monitor central airway problems.

The preoperative physiologic assessment of a patient being considered for surgical resection of lung cancer is important and should be considered due to the immediate preoperative risks from co-morbid cardiopulmonary disease, the long-term risks of pulmonary disability, and the threat to survival due to inadequately treated lung cancer. Current methods involve lung function tests together with ventilation and perfusion (V/Q) scans which include radiation and are expensive and cumbersome.

"Lung cancer is the leading cause of cancer death in the USA and the world and surgery remains the best treatment option for patients with this condition. Predictions of postoperative lung function are crucial to maximize the number of patients that can benefit from surgery and identify patients with such poor respiratory reserve that lung resection would result in an unacceptable quality of life. These preoperative evaluations currently require radionuclide tests of ventilation and perfusion that require administration of radioactive isotopes and not always readily available. Early results of our investigations indicate no significant differences in values calculated with traditional radiospirometric studies and VRI, a simpler, office-based, non-invasive, and radiation-free alternative," said Dr. Rodolfo Morice, MD, at The University of Texas MD Anderson Cancer Center USA.

"The VRI system allows you to monitor and record breath sounds. This non- invasive technique has the potential to diagnose a variety of airway conditions promptly and in a cost effective manner," said Prof. Atul Mehta, Medical Director Lung Transplantation, Vice Chairman and Head of Bronchology Pulmonary, Allergy and Critical Care Medicine Cleveland Clinic, Ohio USA.

The availability of the VRIxp(TM) system in the US, advances our efforts to create a new clinical paradigm in which our technology will be the standard application in a broad line of clinical applications," said Igal Kushnir, President & CEO of Deep Breeze Ltd. "It also represents a significant development in the concerted push by Deep Breeze Ltd. to build a global marketing and sales platform directed at pulmonary medical care. Indeed, the potential for this medical technology to effectively help managing patients is unlimited."

About VRIxp(TM)

The procedure takes only minutes in a physician's office and may be performed repeatedly for continuous monitoring. Results are delivered to the physician immediately and can be stored in a system database for future use. The radiation-free technology has been used in more than 3,500 patients worldwide without any single adverse event.

About Deep Breeze Ltd.

Founded in 2001, Israel-based Deep Breeze Ltd. (http://www.deepbreeze.com) is a privately-held medical device company that is providing advanced pulmonary imaging with its proprietary patented technology, vibration Response Imaging (VRI(TM)). The Company is currently conducting clinical studies globally to evaluate VRI(TM) efficacy in fields such as: general pulmonology, chronic obstructive pulmonary disease, asthma, congestive heart failure, interventional pulmonology, lung cancer, lung transplant and critical care patient management. Deep Breeze Ltd. is researching and developing the VRI(TM) technology to be applied in other organs of the human body.


'/>"/>
SOURCE Deep Breeze Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Breathing Exercises help cardiac patients to breeze through surgery
2. Glaxo launches pills to help smokers quit in 7-12 weeks
3. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
4. Dr Reddy’s Laboratories launches Hyalosy
5. Serum Institute Launches New Tetanus-Diphtheria Vaccine
6. Scottish Health Minister Launches Organ Donor Plan
7. GlaxoSmithKline launches diabetes and cancer drugs
8. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
9. Pfizer Launches Viagra For Lung Disease In UK
10. PM Launches Healthcare Foundation For India
11. African Union Launches A Programme On Acceleration of HIV Prevention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... , ... Mercy College is expanding its Graduate Business Programs to the Bronx ... to high demand: Master of Business Administration (MBA), Master of Organizational Leadership (MSOL) and ... School of Business Graduate Program Chair Dr. Ray Manganelli said: “We believe that people ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Council for Graduate Medical Education (ACGME) that it has received accreditation for its ... accreditation of three residency programs that Memorial is currently pursuing, including Pediatrics and ...
(Date:4/29/2016)... Atlanta, Georgia (PRWEB) , ... April 29, 2016 , ... ... 60 rural hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on ... by Rep. Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House announced efforts ... more information about their loan terms and accounts, and more protections for borrowers. ... federal and private loans, has reached $1.3 trillion, with 43 million Americans holding ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... infants born with severe congenital diaphragmatic hernia have better survival rates if surgery ... diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016 ReportsnReports.com ... 2016" market research report that provides an overview ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
(Date:4/29/2016)... Glycotope GmbH, a clinical-stage immuno-oncology company built ... Dr. Alfredo Zurlo as Chief Medical Officer. ... years clinical experience and a proven track record in ... at Mologen AG where he was Chief Medical Officer ... held various positions at F Hoffmann La Roche and ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... will notably complement the company,s valve repair and ... the move also places Abbott more firmly into ... one of the fastest growing device areas, with ... to its recent report,  Advanced Remote Patient ...
Breaking Medicine Technology: